Treatments of COVID-19 in primary care in the Netherlands
- Conditions
- Patients with symptomatic COVID-19 in the community and in primary care, who are at higher risk of a complicated illness course.MedDRA version: 23.0Level: PTClassification code: 10084268Term: COVID-19 Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- CTIS2022-501559-99-00
- Lead Sponsor
- Maastricht University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 682
Participant is willing and able to give informed consent for participation in the study., Participant is willing and able to comply with all trial procedures., Participant has an e-mail address, mobile phone and a laptop/computer/tablet that allows video calling., A positive test for COVID-19 (can be either RT-PCR, LAMP, antigen or self-test), which was taken fewer than 8 days ago (7 days or less)., The participant experiences symptoms of COVID-19. These symptoms may include, but are not limited to, shortness of breath, general feeling of being unwell, muscle pain, sore throat, diarrhoea, vomiting, fever, running nose, sneezing and coughing, and they must have had them for 7 days or less., Patients aged =18-60 years who are eligible for the annual influenza vaccine., Patients aged =60 years
Currently admitted to hospital, Almost recovered (generally much improved and symptoms now mild or almost absent), Intervention specific (Montelukast): Known hypersensitivity to montelukast, Intervention specific (Montelukast): Concomitant use of montelukast, Intervention specific (Montelukast): Using Fenytoine, Fenobarbital, Rifampicine, Carbamazepine or St John’s wort
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method